Background: The main purpose of the present study is to evaluate whether treatment with long-acting human\nglucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in\nobese subjects with type-2 diabetes.\nMethods: This single-centre retrospective study included 158 obese (body mass index [BMI] ââ?°Â¥ 30 kg/m2) adult\nsubjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study\ninclusion. Data of the Epworth Sleepiness Scale (ESS), anthropometric parameters, glucose-control and metabolic\nparameters were collected at liraglutide initiation (baseline) and at months 1 and 3 after liraglutide initiation.\nResults: Significant reductions in ESS score were achieved at months 1 (âË?â??1.3 Ã?± 2.8, p < 0.001) and 3 (âË?â??1.5 Ã?± 3.0, p < 0.001)\nafter liraglutide introduction. After 3 months of treatment with liraglutide, significant changes in body weight (p < 0.001),\nBMI (p < 0.001), waist (p < 0.001) and neck circumferences (p < 0.005), HbA1c (p < 0.001), mean blood glucose (p < 0.001),\nfasting plasma glucose (p < 0.001), triglycerides (p < 0.01) and total cholesterol (p < 0.001) were achieved.\nConclusions: After 3 months of treatment with liraglutide a significant reduction in EDS was observed in obese\nsubjects with type-2 diabetes. Besides this, significant changes in body weight and metabolic parameters of\ndiabetes control were also accomplished. Further investigation is required to determine whether liraglutide could\nimprove other abnormal sleep patterns and obstructive sleep apnoea.
Loading....